The biosphere is a multinational corporation, with headquarters in San Diego, California, which discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1987, Biosphere was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from the lab, to the manufacturing plant, to the patient. Biosphere’s therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Biosphere pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Biosphere continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illnesses.
To service Europe, the Middle East, and Africa (EMEA), Biosphere’s top management team has decided to establish a new production and shared services facility in Europe. This facility will manufacture products and provide technical product support for the EMEA region. It will also have a small research and development capacity. Biosphere’s top management team is considering locating the new facility in Ireland amongst other European locations.
The establishment of this EMEA SBS Centre is part of Biosphere’s strategy to create a multi-function Shared Business Services organization to support key business functions at a regional level. Regional SBS Centres have already been established for North America and Latin America in Nth Carolina and for Asia Pacific in Singapore. The EMEA SBS Centre will support business transactions in the areas of finance, accounting, procurement, and managed services such as travel and meetings.
cta_question_2
